Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday newspaper round-up: Restrictions, Unemployment, Blood plasma

Sun, 29th Mar 2020 20:57

(Sharecast News) - "Life in Britain will not return to normal for six months, England's deputy chief medical officer has warned, as ministers begin preparing the public for an extended period of lockdown. At the government's daily press conference, Jenny Harries said that strict social distancing rules may have to be in place for between two and three months. But she added that it would be a further three months before all restrictions were lifted, and even then there were likely to be "bumps" as new clusters of cases of coronavirus were identified." - Sunday Times
Unemployment in Britain is set to more than double in coming months, despite government efforts to incentivise employers to keep staff. Economists warn that the rise in the second quarter of the year will be even sharper than during the financial crisis in 2008. Nomura, the investment bank, predicts an unemployment rate of 8% in the April-June quarter, rising to 8.5% in the following three months, from 3.9% in January, as GDP falls sharply. The 8% rate would be the equivalent of an additional 1.4 million people unemployed and a total jobless level of 2.75 million. - Sunday Times

Rolls-Royce is facing a cash flow crisis as the collapse in air travel caused by coronavirus sees half of its revenues evaporate, leaving the FTSE 100 engineer scrambling for cash. Within days of the scale of the crisis becoming clear, Rolls drew down ?2.5bn of funding to boost its liquidity to ?7bn. However, with the company depending on its civil aerospace business for half of its ?15.4bn underlying revenue, it is likely to need further funding as the coronavirus crisis drags on. - Sunday Telegraph

Doctors have drawn up plans to infuse British coronavirus patients and their carers with blood plasma harvested from "hyperimmune" people who have recovered from the infection in an attempt to save lives. The experimental treatment will be directed at patients who are admitted to hospital with pneumonia caused by the virus in the hope that it reduces the number who end up on ventilators in intensive care units (ICUs). - Guardian

"Italy's political leaders from Left to Right have erupted in fury over the EU's minimalist, insulting, and cack-handed response to the Covid-19 pandemic, warning that lack of economic solidarity risks pushing the bloc's festering divisions beyond the point of no return. "Don't make a tragic mistake. The whole European edifice risks losing its raison d'etre," said the Italian premier, Giuseppe Conte, demanding a giant Marshall Plan funded on the EU's joint credit card to relaunch the productive system once the current nightmare is over." - Sunday Telegraph

Scores of Britain's best-known high street food and drink chains will go bust by the end of April unless banks provide immediate finance, the head of the hospitality industry has warned. Kate Nicholls, chief executive of the UK Hospitality trade body, said further failures are 'inevitable' after 80- strong restaurant chain Chiquitos - owned by The Restaurant Group, whose chief executive is ex-HBOS bank boss Andy Hornby - and the 73-outlet Carluccio's lined up administrators. Nicholls said short-term loans from banks are vital to cover costs pending the arrival of Government grant packages. - UK Daily Mail

Synairgen, listed on the London Stock Exchange and worth just ?50m, is starting a clinical trial in hospitals across the UK with a drug it hopes will prevent coronavirus sufferers from falling seriously ill. [...] Synairgen will now test the treatment on 100 patients with coronavirus. Half will be given its new drug, half will get a placebo. Results could arrive in as soon as eight weeks, which could pave the way for a fast-tracked pivotal study in a bigger group of patients and rapid approval. - Sunday Times

More News
20 Jan 2021 21:16

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

Read more
13 Jan 2021 10:24

Synairgen Doses First Patient In Covid-19 Treatment Trial

Synairgen Doses First Patient In Covid-19 Treatment Trial

Read more
11 Jan 2021 20:54

COVID SCIENCE-COVID-19 patients still have symptoms 6 months later; interferon may be helpful treatment after all

By Nancy LapidJan 11 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Half a year later, COVID-19 pat...

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 11:06

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Read more
18 Dec 2020 10:29

Synairgen makes solid progress with Covid-19 treatment

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its phase 3 trial design evaluating SNG001 as a treatment for patients with Covid-19 on Friday, as well as positive progress on its regulatory path.

Read more
18 Nov 2020 13:59

finnCap Interim Profit More Than Doubles; Chair To Step Down

finnCap Interim Profit More Than Doubles; Chair To Step Down

Read more
13 Nov 2020 14:28

Synairgen surges on positive results for Covid-19 treatment

(Sharecast News) - Synairgen shares surged on Friday after data from trials of its inhaled Covid-19 treatment, SNG001, published in The Lancet Respiratory Medicine, showed positive results in hospitalised patients.

Read more
13 Nov 2020 10:24

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Read more
2 Nov 2020 20:03

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

Read more
15 Oct 2020 11:39

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Read more
14 Oct 2020 18:02

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

Read more
29 Sep 2020 12:14

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Read more
9 Sep 2020 16:04

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

Read more
9 Sep 2020 12:23

Synairgen files for another patent on 'SNG001'

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.